Research programme: anti-infectives - Wockhardt

Drug Profile

Research programme: anti-infectives - Wockhardt

Alternative Names: Ketolides - Wockhardt; Oxas - Wockhardt; WCK 2370; WCK 2664; WCK 2832; WCK 2924; WCK 3023; WCK 919; WCK-1734; WCK-4086; WCK-4897; WCK-4918

Latest Information Update: 04 Nov 2017

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Wockhardt
  • Class Ketolides; Oxazolidinones
  • Mechanism of Action DNA gyrase inhibitors; DNA topoisomerase IV inhibitors; Type II DNA topoisomerase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Gram-negative infections
  • Research Nosocomial infections; Urinary tract infections
  • No development reported Bacterial infections; Gram-positive infections; Methicillin-resistant Staphylococcus aureus infections; Skin and soft tissue infections

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for preclinical development in Bacterial-infections in India (PO)
  • 04 Nov 2017 No recent reports of development identified for preclinical development in Gram-positive-infections in India (IV)
  • 04 Nov 2017 No recent reports of development identified for preclinical development in Gram-positive-infections in India (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top